Jennifer Smith is the editor of Oncology Practice, part of MDedge Hematology/Oncology. She was previously the editor of Hematology Times, an editor at Principal Investigators Association, and a reporter at The Oneida Daily Dispatch. She has a BS in journalism.
News
FDA approves ibrutinib plus obinutuzumab for CLL/SLL
The approval is supported by the phase 3 iLLUMINATE trial.
News
EC approves blinatumomab for MRD-positive BCP-ALL
The approval was based on data from the phase 2 BLAST trial.
News
Umbralisib gains FDA breakthrough designation for MZL
Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.
News
Combo treatment may improve quality of life in CTCL
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...
News
Are single agents better than chemo for relapsed/refractory PTCL?
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
Video
Four-drug combo shows durable responses in relapsed/refractory lymphomas
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.
News
FDA approves third trastuzumab biosimilar
The drug is approved for treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
News
Long-term mogamulizumab appears safe, effective in CTCL
LA JOLLA, CALIF. – Investigators said that prolonged treatment with the drug does not appear to pose an increased safety risk.
News
Zanubrutinib receives breakthrough designation for MCL
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
News
Chidamide may be more effective in PTCL than previously thought
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...
Video
Epigenetics is a hot topic at TCLF 2019
LA JOLLA, CALIF. – New developments include using epigenetic therapy to enhance immune checkpoint therapy and using epigenetic-based combination...
News
Registry data favor CHOEP regimen for PTCL
LA JOLLA, CALIF. – Registry data have influenced the treatment of patients with PTCL in the Czech Republic.
News
FDA approves new ALL treatment for children, young adults
The asparagine-specific enzyme is approved as part of a multiagent chemotherapy regimen.
News
FDA expands dasatinib indication to children with Ph+ ALL
The FDA approved dasatinib in combination with chemotherapy for children with newly diagnosed disease.
News
Checkmate 436: Two-drug combo is ‘promising’ for PMBCL
SAN DIEGO – The early results suggest a high overall response to the drug combination.